BioSpace News Archive

Substantial progress on the afami-cel BLA including FDA agreement on plan for confirmatory evidence and favorable feedback on commercial T-cell potency assay - submission now targeted for Q4 2023

Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chair & Chief Executive Officer, and Robert Buckley, Chief Financial Officer, are scheduled to present at Baird’s 2023 Global Healthcare Conference on Wednesday, September 13, 2023, in New York, New York.

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the second quarter ended June 30, 2023.

As per Precedence Research, the active pharmaceutical ingredients market size is predicted to hit around USD 363.68 billion by 2032, and it is expanding at a CAGR of 6.1% from 2023 to 2032.

Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected by Daiichi Sankyo to be a specialty pharmacy partner for VANFLYTA® (quizartinib).

The global regenerative medicine market size is expected to hit around USD 174.72 billion by 2032 with a registered a CAGR of 22.8% from 2023 to 2032.

GenScript Biotech and T-MAXIMUM Biotech, a biotechnology company pioneering universal cell therapies, have formed a strategic collaboration agreement to enable the development of T-MAXIMUM’s development CAR-T cell therapy using GenScript’s CRISPR nucleic acid reagents.

Researchers at City of Hope were awarded $32.3 million from the California Institute for Regenerative Medicine to support three novel Phase 1 clinical trials evaluating innovative cell and gene therapy treatments for patients with HIV, acute myeloid leukemia and severe aplastic anemia.

Carmell Corporation, a regenerative care company announced the successful closing of the previously announced merger with Flagstaff-based Axolotl Biologix, a profitable regenerative medicine company developing products for active soft tissue repair, aesthetics and orthopedic indications.

Allakos Inc., a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, provided a business update and reported financial results for the second quarter ended June 30, 2023.